Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Leuk Res

Retrieve available abstracts of 419 articles:
HTML format



Single Articles


    July 2021
  1. SILVA WF, Silverio A, Duarte BKL, Aguiar TF, et al
    Philadelphia-positive B-lymphoblastic leukemia in a middle-income country - A real-world multicenter cohort.
    Leuk Res. 2021;110:106666.
    PubMed     Abstract available


  2. HARRIS RA, Stevens JM, Pickering DL, Althof PA, et al
    Frequency, variations, and prognostic implications of chromosome 14q32 deletions in chronic lymphocytic leukemia.
    Leuk Res. 2021;110:106665.
    PubMed     Abstract available


  3. SMITH MR, Cronin JF, Weiss RF
    Alternative strategies for optimizing treatment of chronic lymphocytic leukemia with complex clonal architecture.
    Leuk Res. 2021;110:106663.
    PubMed     Abstract available


  4. DEMINA I, Zerkalenkova E, Zhogov V, Lagoyko S, et al
    The use of additional immunophenotypic criteria for the differential diagnosis of Burkitt lymphoma/leukemia: An exemplary case report.
    Leuk Res. 2021;110:106662.
    PubMed    


    June 2021
  5. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
    Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Leuk Res. 2021;109:106650.
    PubMed    


  6. CHENG L, Zeng S, Yan D, Tu L, et al
    Cytarabine and EIP co-administration synergistically reduces viability of acute lymphoblastic leukemia cells with high ERG expression.
    Leuk Res. 2021;109:106649.
    PubMed     Abstract available


  7. ZHANG Y, Feng S
    The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106647.
    PubMed     Abstract available


  8. ZAMANI A, Fattahi Dolatabadi N, Houshmand M, Nabavizadeh N, et al
    miR-324-3p and miR-508-5p expression levels could serve as potential diagnostic and multidrug-resistant biomarkers in childhood acute lymphoblastic leukemia.
    Leuk Res. 2021;109:106643.
    PubMed     Abstract available


  9. GUPTA SK, Singh P, Chhabra R, Verma M, et al
    Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
    Leuk Res. 2021;109:106641.
    PubMed     Abstract available


  10. HUNTER AM, Al Ali N, Mai A, Shah S, et al
    Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
    Leuk Res. 2021;109:106640.
    PubMed    


  11. GENESCA E, Morgades M, Gonzalez-Gil C, Fuster-Tormo F, et al
    Adverse prognostic impact of complex karyotype (>/=3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
    Leuk Res. 2021;109:106612.
    PubMed     Abstract available


  12. SONG J, Shang B, Pei Y, Shi M, et al
    A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Leuk Res. 2021;109:106638.
    PubMed     Abstract available


  13. ISHDORJ G, Nugent Z, Squires M, Kost S, et al
    Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines.
    Leuk Res. 2021;109:106628.
    PubMed     Abstract available


    May 2021
  14. YASUDA S, Najima Y, Konishi T, Yamada Y, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study.
    Leuk Res. 2021;108:106627.
    PubMed     Abstract available


  15. TANG Z, Kanagal-Shamanna R, Tang G, Patel K, et al
    Analytical and clinical performance of chromosomal microarrays compared with FISH panel and conventional karyotyping in patients with chronic lymphocytic leukemia.
    Leuk Res. 2021;108:106616.
    PubMed     Abstract available


  16. FIEGLE E, Crysandt M, Bouillon AS, Silling G, et al
    Successful allogeneic stem cell transplantation of a patient with Werner syndrome and acute myeloid leukemia.
    Leuk Res. 2021 May 5:106609. doi: 10.1016/j.leukres.2021.106609.
    PubMed    


  17. ALI H, Salhotra A, Stein AS, Nakamura R, et al
    Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT.
    Leuk Res. 2021;104:106579.
    PubMed    


  18. ETIENNE G, Rea D, Coiteux V, Guerci-Bresler A, et al
    Ponatinib long-term follow-up of efficacy and safety in CP-CML patients in real world settings in France: The POST-PACE study.
    Leuk Res. 2021;104:106541.
    PubMed    


    April 2021
  19. HOCH REE, Coser VM, Santos IS, de Souza APD, et al
    Lymphoid markers predict prognosis of pediatric and adolescent acute myeloid leukemia.
    Leuk Res. 2021;107:106603.
    PubMed     Abstract available


  20. HELALY NA, Esheba NE, Ammo DEA, Elwan NM, et al
    High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia.
    Leuk Res. 2021;107:106604.
    PubMed     Abstract available


  21. SPEROTTO A, Gottardi M, Candoni A, Toffoletti E, et al
    WT1 - Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant.
    Leuk Res. 2021;108:106587.
    PubMed    


  22. VACHHANI P, Baron J, Freyer CW, Miller A, et al
    A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia.
    Leuk Res. 2021;107:106588.
    PubMed     Abstract available


  23. CHEN P, Redd L, Schmidt Y, Koduru P, et al
    MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.
    Leuk Res. 2021;106:106584.
    PubMed     Abstract available


  24. PETRICK L, Imani P, Perttula K, Yano Y, et al
    Untargeted metabolomics of newborn dried blood spots reveals sex-specific associations with pediatric acute myeloid leukemia.
    Leuk Res. 2021;106:106585.
    PubMed     Abstract available


  25. GARCIA JS, Swords RT, Roboz GJ, Jacoby MA, et al
    Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
    Leuk Res. 2021 Apr 22:106581. doi: 10.1016/j.leukres.2021.106581.
    PubMed    


  26. KRISTENSEN D, Nielsen LB, Roug AS, Kristensen TC, et al
    The prognostic impact of anthropometrics in acute myeloid leukemia treated with intensive chemotherapy - A Danish nationwide cohort study.
    Leuk Res. 2021;106:106567.
    PubMed    


  27. KIM YJ, Jung SH, Hur EH, Choi EJ, et al
    Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome.
    Leuk Res. 2021;103:106540.
    PubMed     Abstract available


    March 2021
  28. PARK S, Choi EJ, Lee H, Jo DY, et al
    Treatment-free remission of chronic myeloid leukemia in real-world practice by the detection limit of MR4.3.
    Leuk Res. 2021;105:106578.
    PubMed     Abstract available


  29. MUUS P, Langemeijer S, van Bijnen S, Blijlevens N, et al
    A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia.
    Leuk Res. 2021;105:106573.
    PubMed     Abstract available


  30. ROBAK E, Jesionek-Kupnicka D, Iskierka-Jazdzewska E, Janus A, et al
    Cutaneous leukocytoclastic vasculitis at diagnosis of hairy cell leukemia successfully treated with vemurafenib and rituximab.
    Leuk Res. 2021;104:106571.
    PubMed    


  31. MOHTY R, Massoud R, Chakhachiro Z, Mahfouz R, et al
    Risk adapted therapeutic strategy in newly diagnosed acute myeloid leukemia: Refining the outcomes of ELN 2017 intermediate-risk patients.
    Leuk Res. 2021;105:106568.
    PubMed     Abstract available


  32. NI J, Hong J, Li Q, Zeng Q, et al
    Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia.
    Leuk Res. 2021;105:106564.
    PubMed     Abstract available


  33. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480].
    Leuk Res. 2021 Mar 26:106563. doi: 10.1016/j.leukres.2021.106563.
    PubMed    


  34. OZKAN T, Hekmatshoar Y, Karabay AZ, Koc A, et al
    Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
    Leuk Res. 2021;102:106523.
    PubMed     Abstract available


    February 2021
  35. REID JH, Perissinotti AJ, Benitez LL, Boyer D, et al
    Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
    Leuk Res. 2021;103:106539.
    PubMed     Abstract available


  36. HUANG SJ, Gerrie AS, Young S, Tucker T, et al
    Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
    Leuk Res. 2021;103:106538.
    PubMed     Abstract available


  37. SHIMIZU H, Yokohama A, Ishizaki T, Hatsumi N, et al
    Clonal evolution detected with conventional cytogenetic analysis is a potent prognostic factor in adult patients with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2021;103:106535.
    PubMed     Abstract available


  38. PAROVICHNIKOVA EN, Troitskaya VV, Gavrilina OA, Sokolov AN, et al
    The outcome of Ph-negative acute lymphoblastic leukemia presenting during pregnancy and treated on the Russian prospective multicenter trial RALL-2009.
    Leuk Res. 2021;104:106536.
    PubMed     Abstract available


  39. JEURKAR C, Wilde L, Leiby BE, Banks J, et al
    Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival.
    Leuk Res. 2021;103:106533.
    PubMed     Abstract available


  40. BOULIGNY IM, Mehta V, Isom S, Ellis LR, et al
    Efficacy of 10-day decitabine in acute myeloid leukemia.
    Leuk Res. 2021;103:106524.
    PubMed     Abstract available


  41. SOLMAN IG, Blum LK, Burger JA, Kipps TJ, et al
    Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia.
    Leuk Res. 2021;102:106520.
    PubMed     Abstract available


  42. MOORE JE, Delibert K, Baran AM, Evans AG, et al
    Targeted therapy for treatment of patients with classical hairy cell leukemia.
    Leuk Res. 2021;102:106522.
    PubMed     Abstract available


  43. SEGURO FS, Maciel FVR, Santos FM, Abdo ANR, et al
    MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
    Leuk Res. 2021;101:106516.
    PubMed     Abstract available


    January 2021
  44. MARTIN-MORO F, Nunez-Torron C, Perez-Lamas L, Jimenez-Chillon C, et al
    The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid.
    Leuk Res. 2021;101:106518.
    PubMed    


  45. OCHS MA, Perissinotti AJ, Marini BL, Burke PW, et al
    Impact of high dose cytarabine dosing strategies in obese patients with acute myeloid leukemia.
    Leuk Res. 2021;102:106517.
    PubMed     Abstract available


  46. GHALESARDI OK, Khosravi A, Azizi E, Ahmadi SE, et al
    The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
    Leuk Res. 2021;101:106512.
    PubMed     Abstract available


  47. MONTALBAN-BRAVO G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, et al
    Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia.
    Leuk Res. 2021;101:106511.
    PubMed     Abstract available


  48. ZENT CS, Ross DM
    Changing of the guard: Leukemia Research 2021.
    Leuk Res. 2021 Jan 13:106510. doi: 10.1016/j.leukres.2021.106510.
    PubMed    


  49. ACHA P, Hoyos M, Pratcorona M, Fuster-Tormo F, et al
    Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes.
    Leuk Res. 2021;101:106492.
    PubMed    


  50. PELCOVITS A, Pandita A, Farmakiotis D, Egan P, et al
    Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR.
    Leuk Res. 2021;100:106473.
    PubMed    


    December 2020
  51. MARCONI G, De Polo S, Martinelli G, Nanni J, et al
    Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.
    Leuk Res. 2020;101:106497.
    PubMed     Abstract available


  52. ADRIANZEN-HERRERA D, Jordan-Bruno X, Devitt KA, Conant JL, et al
    Acquired BCR-ABL1 fusion and IDH1 clonal evolution following BCL2 inhibitor treatment in refractory acute myeloid leukemia.
    Leuk Res. 2020;100:106494.
    PubMed    


  53. YASUDA H, Morishita S, Mori Y, Tsukune Y, et al
    JAK2/CALR/SF3B1 triple-mutated myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis evolving to myelofibrosis and SF3B1 single-mutated acute myeloid leukemia: Evidence of a pre-JAK2 clone.
    Leuk Res. 2020;100:106496.
    PubMed    


  54. DJAMAI H, Berrou J, Dupont M, Kaci A, et al
    Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Leuk Res. 2020;100:106490.
    PubMed     Abstract available


  55. DEMINA I, Voropayev A, Semchenkova A, Zerkalenkova E, et al
    Additional flow cytometric studies for differential diagnosis between Burkitt lymphoma/leukemia and B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2020;100:106491.
    PubMed     Abstract available


  56. YEE K, Papayannidis C, Vey N, Dickinson MJ, et al
    Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study small star, filled.
    Leuk Res. 2020;100:106489.
    PubMed     Abstract available


  57. SHAO H, Wang W, Song J, Tang G, et al
    Myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement.
    Leuk Res. 2020;99:106460.
    PubMed     Abstract available


  58. KIRKIZLAR TA, Akalin H, Kirkizlar O, Ozkalemkas F, et al
    Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia.
    Leuk Res. 2020;99:106463.
    PubMed     Abstract available


  59. MALLER B, Bigness A, Moino D, Greene J, et al
    Sweet's syndrome associated with hematological malignancies.
    Leuk Res. 2020;99:106461.
    PubMed     Abstract available


    November 2020
  60. BENEDETTI E, Barate C, Bruno B, Bramanti E, et al
    Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.
    Leuk Res. 2020;100:106488.
    PubMed    


  61. BERGSTROM CP, Dahiya S, Chen W, Zhang CC, et al
    The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
    Leuk Res. 2020;100:106480.
    PubMed     Abstract available


  62. YANAGISAWA B, Perkins B, Karantanos T, Levis M, et al
    Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes.
    Leuk Res. 2020;99:106477.
    PubMed     Abstract available


  63. OBAMA K, Tabuchi T, Inoue H
    Prognostic impact of red cell distribution width in adult T-cell leukemia/lymphoma.
    Leuk Res. 2020;99:106474.
    PubMed    


    October 2020
  64. KAUFFMAN MR, Nazemidashtarjandi S, Ghazanfari D, Allen AE, et al
    Evidence that knock down of GSK-3beta in Chronic Myelogenous Leukemia cells augments IFN-gamma-induced apoptosis.
    Leuk Res. 2020;99:106464.
    PubMed     Abstract available


  65. DE BELLIS E, Ottone T, Mercante L, Falconi G, et al
    Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia.
    Leuk Res. 2020;99:106462.
    PubMed     Abstract available


    September 2020
  66. MANLEY PW, Barys L, Cowan-Jacob SW
    The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Leuk Res. 2020;98:106458.
    PubMed     Abstract available


  67. WEI L, Cong J, Yang L, Ye J, et al
    Corrigendum to "SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type" [Leukemia Res. 96 (2020) 106422].
    Leuk Res. 2020 Sep 24:106446. doi: 10.1016/j.leukres.2020.106446.
    PubMed    


  68. TREMBLAY D, Feld J, Dougherty M, Czaplinska T, et al
    Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm.
    Leuk Res. 2020;98:106456.
    PubMed    


  69. MENGHRAJANI K, Zhang Y, Famulare C, Devlin SM, et al
    Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.
    Leuk Res. 2020;98:106453.
    PubMed     Abstract available


  70. CHERNG HJ, Jain N, Thakral B, Muzzafar T, et al
    Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia.
    Leuk Res. 2020;98:106445.
    PubMed    


  71. BOYD K, Parcell B, Tauro S
    Immunosuppression in hematological cancer patients with Covid-19 -Uncomplicated infections but delayed viral clearance?
    Leuk Res. 2020;96:106407.
    PubMed    


  72. BROWN AL, Hiwase DK
    What's germane in the germline? Finding clinically relevant germline variants in myeloid neoplasms from tumor only screening.
    Leuk Res. 2020;96:106431.
    PubMed    


  73. NAGAHARU K, Izumi T, Ueda M, Usui E, et al
    High expression of c-Myc in chronic lymphocytic leukaemia with t(8;14)(q24.1;q32): A case report.
    Leuk Res. 2020;96:106424.
    PubMed    


    August 2020
  74. MAGANTI H, Visram A, Shorr R, Fulcher J, et al
    Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies.
    Leuk Res. 2020;97:106442.
    PubMed     Abstract available


  75. CICCARELLI BT, Hu T, Wang Q, Kim JJ, et al
    Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine bone marrow transplantation model of CML.
    Leuk Res. 2020;97:106440.
    PubMed     Abstract available


  76. SOLMAN IG, Blum LK, Hoh HY, Kipps TJ, et al
    Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2020;97:106432.
    PubMed     Abstract available


  77. DEEREN D
    FLAG-Ida is back in.
    Leuk Res. 2020;95:106400.
    PubMed    


  78. MOLICA S, Baumann TS, Lentini M, Levato L, et al
    The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.
    Leuk Res. 2020;95:106401.
    PubMed    


    July 2020
  79. CHANAS-LARUE A, Villalpando-Rodriguez GE, Henson ES, Johnston JB, et al
    Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Leuk Res. 2020;96:106423.
    PubMed     Abstract available


  80. TRAN AA, Miljkovic M, Prasad V
    Analysis of estimated clinical benefit of newly approved drugs for US patients with acute myeloid leukemia.
    Leuk Res. 2020;96:106420.
    PubMed     Abstract available


  81. SABNIS HS, Minson KA, Monroe C, Allen K, et al
    A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
    Leuk Res. 2020;96:106421.
    PubMed     Abstract available


  82. D'ANGELO CR, Hall A, Woo KM, Kim K, et al
    Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
    Leuk Res. 2020;96:106419.
    PubMed     Abstract available


  83. WANG Y, Luo H, Wei M, Becker M, et al
    IL-33/IL1RL1 axis regulates cell survival through the p38 MAPK pathway in acute myeloid leukemia.
    Leuk Res. 2020;96:106409.
    PubMed     Abstract available


  84. CASELLAS ROMAN HL, Venugopal K, Feng Y, Shabashvili DE, et al
    DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
    Leuk Res. 2020;94:106372.
    PubMed    


  85. GEORGE G, Rezazadeh A, Zook F, Pearl N, et al
    Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study.
    Leuk Res. 2020;94:106368.
    PubMed    


    June 2020
  86. KALLEN ME, Koka R, Singh Z, Sanchez-Petitto G, et al
    Teenage mutant neutrophilic precursors: Leukemia cutis with IDH2 mutation on enasidenib therapy.
    Leuk Res. 2020;96:106406.
    PubMed    


  87. BRITT A, Mohyuddin GR, McClune B, Singh A, et al
    Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Leuk Res. 2020;95:106402.
    PubMed     Abstract available


  88. ZHENG FY, Lu AD, Zuo YX, Jia YP, et al
    Impact of tyrosine kinase inhibitors on the statural growth in children with acute lymphoblastic leukemia.
    Leuk Res. 2020;95:106405.
    PubMed     Abstract available


  89. GOLDBERG AD, Atallah E, Rizzieri D, Walter RB, et al
    Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
    Leuk Res. 2020;95:106385.
    PubMed     Abstract available


    May 2020
  90. O'CONNOR-BYRNE N, Quinn J, Glavey SV, Lavin M, et al
    Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy.
    Leuk Res. 2020;95:106390.
    PubMed    


  91. SOTO-MERCADO V, Mendivil-Perez M, Jimenez-Del-Rio M, Fox JE, et al
    Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism.
    Leuk Res. 2020;95:106389.
    PubMed     Abstract available


  92. AGUILERA-DIAZ A, Larrayoz MJ, Palomino-Echeverria S, Vazquez I, et al
    Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data.
    Leuk Res. 2020;95:106386.
    PubMed     Abstract available


  93. SAITO T, Itoh M, Tohda S
    Metformin suppresses the growth of leukemia cells partly through downregulation of AXL receptor tyrosine kinase.
    Leuk Res. 2020;94:106383.
    PubMed     Abstract available


  94. WANG X, Resendes NM, Shanahan L, Hutchinson L, et al
    Chronic neutrophilic leukemia, a rare case of leukocytosis.
    Leuk Res. 2020;94:106384.
    PubMed    


  95. NAVADA SC, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, et al
    Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study.
    Leuk Res. 2020;94:106369.
    PubMed     Abstract available


  96. NAYMAGON L, Mascarenhas J
    Hemorrhage in acute promyelocytic leukemia: Can it be predicted and prevented?
    Leuk Res. 2020;94:106356.
    PubMed     Abstract available


  97. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    Corrigendum to "STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype" [Leuk. Res. 78 (2019) 21-23].
    Leuk Res. 2020 May 4:106148. doi: 10.1016/j.leukres.2019.
    PubMed    


  98. TALATI C, Goldberg AD, Przespolewski A, Chan O, et al
    Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy.
    Leuk Res. 2020;93:106367.
    PubMed     Abstract available


    April 2020
  99. PANEESHA S, Pratt G, Parry H, Moss P, et al
    Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.
    Leuk Res. 2020;93:106366.
    PubMed    


  100. FRANCH-SARTO M, Anglada Escalona JR, Tuset Beltran V, Ribera Santasusana JM, et al
    A unique case of relapse of plasma cell leukemia in the vitreous humor.
    Leuk Res. 2020;93:106357.
    PubMed    


  101. OLIVA EN, Tripepi GL
    Letter to the Editor on the original article "A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia" by Bryant Al, et al. 2018.
    Leuk Res. 2020;93:106355.
    PubMed    


  102. DRUHAN LJ, Lance A, Hamilton A, Steuerwald NM, et al
    Altered splicing and intronic polyadenylation of CSF3R via a cryptic exon in acute myeloid leukemia.
    Leuk Res. 2020;92:106349.
    PubMed    


  103. BRUNNER AM
    The highs and lows of venetoclax with hypomethylating agents for refractory AML.
    Leuk Res. 2020;91:106320.
    PubMed    


    March 2020
  104. GAVILLET M, Carr Klappert J, Spertini O, Blum S, et al
    Acute leukemia in the time of COVID-19.
    Leuk Res. 2020;92:106353.
    PubMed    


  105. YANG W, Xie J, Hou R, Chen X, et al
    Disulfiram/cytarabine eradicates a subset of acute myeloid leukemia stem cells with high aldehyde dehydrogenase expression.
    Leuk Res. 2020;92:106351.
    PubMed     Abstract available


  106. SODERLUND S, Persson I, Ilander M, Guilhot J, et al
    Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy.
    Leuk Res. 2020;90:106310.
    PubMed     Abstract available


    February 2020
  107. DA FONSECA BASTOS ACS, da Silva Rezende AC, Ferreira LB, Blunck CB, et al
    Osteopontin-c is overexpressed in KMT2A-AFF1 positive pediatric B-cell lymphoblastic leukemia when compared to those with ETV6-RUNX1".
    Leuk Res. 2020;91:106316.
    PubMed    


  108. GRIFFITHS EA, Carraway HE, Chandhok NS, Prebet T, et al
    Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Leuk Res. 2020;91:106339.
    PubMed     Abstract available


  109. OZGUR YURTTAS N, Eskazan AE
    Novel therapeutic approaches in chronic myeloid leukemia.
    Leuk Res. 2020;91:106337.
    PubMed     Abstract available


  110. DEEREN D, Balabanov S, Nickel K, Giannopoulou C, et al
    Management of patients with acute lymphoblastic leukemia in routine clinical practice: Minimal residual disease testing, treatment patterns and clinical outcomes in Belgium, Greece and Switzerland.
    Leuk Res. 2020;91:106334.
    PubMed     Abstract available


  111. ZHANG Y, Xue S, Liu F, Wang J, et al
    Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Res. 2020;91:106332.
    PubMed    


  112. HUANG SJ, Gerrie AS, Young S, Tucker T, et al
    Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
    Leuk Res. 2020;91:106335.
    PubMed     Abstract available


  113. BAI L, Cheng YF, Lu AD, Suo P, et al
    Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)/MLL-rearranged B-cell acute lymphoblastic leukemia.
    Leuk Res. 2020;91:106333.
    PubMed     Abstract available


  114. LOU Y, Shao L, Mao L, Lu Y, et al
    Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study.
    Leuk Res. 2020;91:106317.
    PubMed    


  115. SOLH MM, Solomon SR, Morris LE, Zhang X, et al
    Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).
    Leuk Res. 2020 Feb 14:106318. doi: 10.1016/j.leukres.2020.106318.
    PubMed     Abstract available


  116. QASRAWI A, Gomes V, Chacko CA, Mansour A, et al
    Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database.
    Leuk Res. 2020;89:106301.
    PubMed     Abstract available


  117. GORDON MJ, Sitlinger A, Salous T, Alqahtani H, et al
    A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Leuk Res. 2020;89:106302.
    PubMed    


    January 2020
  118. SHALLIS RM, Patel TH, Podoltsev NA, Xu ML, et al
    Disseminated, yet dissembled: Rare infections behind the veil of classical hairy cell leukemia.
    Leuk Res. 2020;90:106315.
    PubMed    


  119. GAUT D, Burkenroad A, Duong T, Feammelli J, et al
    Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
    Leuk Res. 2020;90:106314.
    PubMed     Abstract available


  120. SCHECKEL CJ, Meyer M, Betcher JA, Al-Kali A, et al
    Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
    Leuk Res. 2020;90:106300.
    PubMed     Abstract available


  121. ZHU Y, Gao Q, Hu J, Liu X, et al
    Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience.
    Leuk Res. 2020;90:106299.
    PubMed     Abstract available


  122. SAYGIN C, Grieselhuber N, Blachly J, Byrd JC, et al
    Outcomes of the cyclophosphamide, vincristine, prednisone (CVP) +/- rituximab (R-CVP) regimen in older patients with newly diagnosed Ph- acute lymphoblastic leukemia.
    Leuk Res. 2020;89:106297.
    PubMed    


  123. SEIPEL K, Messerli C, Wiedemann G, Bacher U, et al
    MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
    Leuk Res. 2020;89:106296.
    PubMed     Abstract available


  124. HILLIS CM, Jackson Chornenki NL, Bence-Bruckler I, Busque L, et al
    The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.
    Leuk Res. 2020;88:106285.
    PubMed    


    December 2019
  125. BODROG A, Zhang B, Liu L, Casulo C, et al
    A case of Burkitt Leukemia: Revisiting the prognostic value of lactate dehydrogenase.
    Leuk Res. 2019;89:106295.
    PubMed    


  126. JASKOVA Z, Pavlova S, Malcikova J, Brychtova Y, et al
    PRIMA-1(MET) cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cells.
    Leuk Res. 2019;89:106288.
    PubMed     Abstract available


    November 2019
  127. JABBOUR E, Gokbuget N, Advani A, Stelljes M, et al
    Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
    Leuk Res. 2019;88:106283.
    PubMed     Abstract available


  128. URESHINO H, Shindo T, Kimura S
    Role of cancer immunology in chronic myelogenous leukemia.
    Leuk Res. 2019;88:106273.
    PubMed     Abstract available


  129. ZENG H, Wu H, Yan M, Tang L, et al
    Characterization of a 4 lncRNAs-based prognostic risk scoring system in adults with acute myeloid leukemia.
    Leuk Res. 2019;88:106261.
    PubMed     Abstract available


  130. QUENTMEIER H, Pommerenke C, Dirks WG, Fahnrich S, et al
    DNMT3A R882H mutation in acute myeloid leukemia cell line SET-2.
    Leuk Res. 2019;88:106270.
    PubMed    


  131. MASSE A, Roulin L, Pasanisi J, Penneroux J, et al
    BET inhibitors impair leukemic stem cell function only in defined oncogenic subgroups of acute myeloid leukaemias.
    Leuk Res. 2019;87:106269.
    PubMed     Abstract available


  132. YANO Y, Schiffman C, Grigoryan H, Hayes J, et al
    Untargeted adductomics of newborn dried blood spots identifies modifications to human serum albumin associated with childhood leukemia.
    Leuk Res. 2019;88:106268.
    PubMed     Abstract available


    October 2019
  133. WANG G, Li X, Song L, Pan H, et al
    Long noncoding RNA MIAT promotes the progression of acute myeloid leukemia by negatively regulating miR-495.
    Leuk Res. 2019;87:106265.
    PubMed     Abstract available


  134. JEONG D, Lee DS, Kim N, Choi S, et al
    Corrigendum to "Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: Genetic background of pediatric AML" [Leuk. Res. 85 (2019) (October) 106210].
    Leuk Res. 2019 Oct 28:106249. doi: 10.1016/j.leukres.2019.106249.
    PubMed    


  135. MIYAMURA T, Kudo K, Tabuchi K, Ishida H, et al
    Hematopoietic stem cell transplantation for pediatric acute myeloid leukemia patients with KMT2A rearrangement; A nationwide retrospective analysis in Japan.
    Leuk Res. 2019;87:106263.
    PubMed     Abstract available


  136. WILLIS C, Menon J, Unni S, Au T, et al
    Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.
    Leuk Res. 2019;87:106262.
    PubMed     Abstract available


  137. LIMVORAPITAK W, Owattanapanich W, Utchariyaprasit E, Niparuck P, et al
    Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia - A multicenter prospective registry in Thai population.
    Leuk Res. 2019;87:106235.
    PubMed     Abstract available


  138. KATSARAKI K, Artemaki PI, Papageorgiou SG, Pappa V, et al
    Identification of a novel, internal tRNA-derived RNA fragment as a new prognostic and screening biomarker in chronic lymphocytic leukemia, using an innovative quantitative real-time PCR assay.
    Leuk Res. 2019;87:106234.
    PubMed     Abstract available


  139. PREZZO A, Cavaliere FM, Bilotta C, Pentimalli TM, et al
    Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Leuk Res. 2019;87:106233.
    PubMed     Abstract available


    September 2019
  140. GATINEAU-SAILLIANT S, Glisovic S, Gagne V, Laverdiere C, et al
    Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study.
    Leuk Res. 2019;86:106228.
    PubMed    


  141. NAKAMURA R, Gendzekhadze K, Palmer J, Tsai NC, et al
    Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
    Leuk Res. 2019;87:106230.
    PubMed     Abstract available


  142. LIU M, Liao H, Chen Y, Lin Z, et al
    Treatment of human T-cell acute lymphoblastic leukemia cells with CFTR inhibitor CFTRinh-172.
    Leuk Res. 2019;86:106225.
    PubMed     Abstract available


  143. MARCOLIN R, Guolo F, Minetto P, Clavio M, et al
    A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
    Leuk Res. 2019;86:106223.
    PubMed     Abstract available


  144. BESTACH Y, Toloza MJ, Ferri C, Larripa I, et al
    The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib.
    Leuk Res. 2019;86:106221.
    PubMed    


    August 2019
  145. YANG L, Kost SEF, Beiggi S, Zhang Y, et al
    Buccal cell telomere length is not a useful marker for comorbidities in chronic lymphocytic leukemia.
    Leuk Res. 2019;86:106220.
    PubMed    


  146. KRUZOVA L, Schneiderova P, Holzerova M, Vatolikova M, et al
    Complex karyotype as a predictor of high-risk chronic lymphocytic leukemia: A single center experience over 12 years.
    Leuk Res. 2019;85:106218.
    PubMed     Abstract available


  147. JEONG D, Lee DS, Kim N, Choi S, et al
    Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: Genetic background of pediatric AML.
    Leuk Res. 2019;85:106210.
    PubMed    


  148. STRATMANN J, van Kann E, Rummelt C, Koschade S, et al
    Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure.
    Leuk Res. 2019;85:106192.
    PubMed     Abstract available


  149. SHANG J, Chen WM, Liu S, Wang ZH, et al
    CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy.
    Leuk Res. 2019;85:106198.
    PubMed     Abstract available


  150. DEANGELO DJ, Walker AR, Schlenk RF, Sierra J, et al
    Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
    Leuk Res. 2019;85:106197.
    PubMed     Abstract available


    July 2019
  151. OTOUKESH S, Salhotra A, Marcucci G, Forman SJ, et al
    The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
    Leuk Res. 2019;84:106196.
    PubMed    


  152. YUN S, Sharma R, Chan O, Vincelette ND, et al
    Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).
    Leuk Res. 2019;84:106194.
    PubMed     Abstract available


  153. HUANG SJ, Chan J, Bruyere H, Allan LL, et al
    Chronic lymphocytic leukemia patients with HLA-B27 referred for allogeneic hematopoietic stem cell transplantation do not have worse outcomes: Results of a population-based case series analysis in British Columbia, Canada.
    Leuk Res. 2019;84:106193.
    PubMed     Abstract available


  154. HWANG SM, Kim SM, Nam Y, Kim J, et al
    Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Leuk Res. 2019;84:106190.
    PubMed     Abstract available


  155. VIJAY V, Miller R, Vue GS, Pezeshkian MB, et al
    Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia.
    Leuk Res. 2019;84:106180.
    PubMed     Abstract available


    June 2019
  156. JAIN P, Gu J, Kanagal-Shamanna R, Tang Z, et al
    Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph++) adult B cell acute lymPh+oblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens.
    Leuk Res. 2019;84:106176.
    PubMed     Abstract available


  157. HUTMACHER C, Volta L, Rinaldi F, Murer P, et al
    Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
    Leuk Res. 2019;84:106178.
    PubMed     Abstract available


  158. MITRAKOS A, Kattamis A, Katsibardi K, Papadhimitriou S, et al
    High resolution Chromosomal Microarray Analysis (CMA) enhances the genetic profile of pediatric B-cell Acute Lymphoblastic Leukemia patients.
    Leuk Res. 2019;83:106177.
    PubMed     Abstract available


  159. HAMBLEY BC, Norsworthy KJ, Jasem J, Zimmerman JW, et al
    Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
    Leuk Res. 2019;83:106174.
    PubMed    


  160. KINSELLA FAM, Inman CF, Gudger A, Chan YT, et al
    Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
    Leuk Res. 2019;83:106173.
    PubMed     Abstract available


  161. D'ARENA G, Valvano L, Vitale C, Coscia M, et al
    CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results.
    Leuk Res. 2019;83:106169.
    PubMed    


  162. LOU Y, Tong H, Yu W, Wei J, et al
    Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Leuk Res. 2019;83:106168.
    PubMed     Abstract available


  163. DA SILVA WF, Neto AC, da Rosa LI, de Siqueira IA, et al
    Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.
    Leuk Res. 2019;83:106165.
    PubMed     Abstract available


  164. FANG J, Zhang R, Wang H, Hong M, et al
    Corrigendum to 'Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study.' [L
    Leuk Res. 2019;81:107.
    PubMed    


  165. CHIRON D, Jego G, Pellat-Deuceunynck C
    Corrigendum to 'Toll-like receptors Expression and involvement in Multiple Myeloma' [Leukemia Research 34 (2010)1545-1550].
    Leuk Res. 2019;81:106.
    PubMed    


    May 2019
  166. VASCONCELOS FC, Bonecker ST, de Souza PS, Scheiner MAM, et al
    Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients.
    Leuk Res. 2019;82:33-35.
    PubMed    


  167. TADMOR T, Levy I, Herishanu Y, Goldschmidt N, et al
    Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
    Leuk Res. 2019;82:24-28.
    PubMed     Abstract available


  168. JAMY O, Sarmad R, Costa L
    Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors.
    Leuk Res. 2019;82:1-6.
    PubMed     Abstract available


  169. WANG YH, Liang JD, Sheng WH, Tien FM, et al
    Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia.
    Leuk Res. 2019;81:95-97.
    PubMed    


  170. ZINZANI PL, Rambaldi A, Gaidano G, Girmenia C, et al
    Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.
    Leuk Res. 2019;81:88-94.
    PubMed     Abstract available


  171. FLYNN KE, Mauro MJ, George G, Hinman A, et al
    Patients' perspectives on the definition of cure in chronic myeloid leukemia.
    Leuk Res. 2019;80:40-42.
    PubMed    


    April 2019
  172. SPUNAROVA M, Tom N, Pavlova S, Mraz M, et al
    Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Leuk Res. 2019;81:75-81.
    PubMed     Abstract available


  173. GERDS AT, Tauchi T, Ritchie E, Deininger M, et al
    Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44].
    Leuk Res. 2019 Apr 24. pii: S0145-2126(19)30070.
    PubMed    


  174. STEVENS B, Winters A, Gutman JA, Fullerton A, et al
    Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis.
    Leuk Res. 2019;81:43-49.
    PubMed     Abstract available


  175. MOSHAVER B, Wouters RF, Kelder A, Ossenkoppele GJ, et al
    Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Leuk Res. 2019;81:27-34.
    PubMed     Abstract available


  176. TURCSANYI P, Kriegova E, Kudelka M, Radvansky M, et al
    Improving risk-stratification of patients with chronic lymphocytic leukemia using multivariate patient similarity networks.
    Leuk Res. 2019;79:60-68.
    PubMed     Abstract available


  177. BAI Y, Shi M, Yang X, Zhang W, et al
    The value of FDP/FIB and D-dimer/FIB ratios in predicting high-risk APL-related thrombosis.
    Leuk Res. 2019;79:34-37.
    PubMed     Abstract available


  178. YUANXIN Y, Yanhong Z, Qin Z, Sishi T, et al
    Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
    Leuk Res. 2019;79:6-16.
    PubMed     Abstract available


    March 2019
  179. WANG S, Wang C, Wang W, Hao Q, et al
    High RASD1 transcript levels at diagnosis predicted poor survival in adult B-cell acute lymphoblastic leukemia patients.
    Leuk Res. 2019;80:26-32.
    PubMed     Abstract available


  180. GLEIXNER KV, Sadovnik I, Schneeweiss M, Eisenwort G, et al
    A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1(T315I) in Ph+ CML.
    Leuk Res. 2019;78:36-44.
    PubMed     Abstract available


    February 2019
  181. JARAMILLO AC, Cloos J, Lemos C, Stam RW, et al
    Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between BCRP, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
    Leuk Res. 2019;79:45-51.
    PubMed     Abstract available


  182. KING AC, Pappacena JJ, Tallman MS, Park JH, et al
    Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
    Leuk Res. 2019;79:27-33.
    PubMed     Abstract available


  183. SPACEK M, Obrtlikova P, Hrobkova S, Cmunt E, et al
    Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab.
    Leuk Res. 2019;79:17-21.
    PubMed     Abstract available


  184. RADIVOYEVITCH T, Jorgensen TN, Lindner DJ, Maciejewski JP, et al
    Chronic myeloid leukemia: Two mysteries.
    Leuk Res. 2019;79:3-5.
    PubMed    


  185. DIAB M, Schiffer CA
    The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.
    Leuk Res. 2019;79:1-2.
    PubMed    


  186. DRUSBOSKY LM, Vidva R, Gera S, Lakshminarayana AV, et al
    Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
    Leuk Res. 2019;77:42-50.
    PubMed     Abstract available


  187. SAYAR H, Cripe LD, Saliba AN, Abu Zaid M, et al
    Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.
    Leuk Res. 2019;77:30-33.
    PubMed    


  188. LUO H, Zhang S, Li K, Chen XH, et al
    A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia.
    Leuk Res. 2019;77:14-16.
    PubMed    


    January 2019
  189. BELL JA, Galaznik A, Farrelly E, Blazer M, et al
    A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
    Leuk Res. 2019;78:45-51.
    PubMed     Abstract available


  190. MEDEIROS BC, Othus M, Tallman MS, Sun Z, et al
    The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).
    Leuk Res. 2019;78:29-33.
    PubMed     Abstract available


  191. BUDNIK J, Milano MT
    A registry-based analysis of survival outcomes in mast cell leukemia.
    Leuk Res. 2019;78:24-28.
    PubMed     Abstract available


  192. CIANGOLA G, Gurnari C, Paterno G, Mirabile M, et al
    STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype.
    Leuk Res. 2019;78:21-23.
    PubMed    


  193. LI L, Cui Y, Shen J, Dobson H, et al
    Evidence for activated Lck protein tyrosine kinase as the driver of proliferation in acute myeloid leukemia cell, CTV-1.
    Leuk Res. 2019;78:12-20.
    PubMed     Abstract available


  194. KUMAR A, Drusbosky LM, Meacham A, Turcotte M, et al
    Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
    Leuk Res. 2019;78:3-11.
    PubMed     Abstract available


  195. HENRY D, Brumaire S, Hu X
    Involvement of pRb-E2F pathway in green tea extract-induced growth inhibition of human myeloid leukemia cells.
    Leuk Res. 2019;77:34-41.
    PubMed     Abstract available


  196. FRIES C, Burack R
    An evolving technology for an evolving disease: A commentary on NGS-based MRD evaluation in B-ALL.
    Leuk Res. 2019;76:105-106.
    PubMed    


  197. HEIBLIG M, Sujobert P, Hayette S, Balsat M, et al
    Impact of NPM1 mutation subtypes on treatment outcome in AML: The Lyon-University Hospital experience.
    Leuk Res. 2019;76:29-32.
    PubMed    


  198. MARTINEZ-CUADRON D, Gil C, Serrano J, Rodriguez G, et al
    A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
    Leuk Res. 2019;76:1-10.
    PubMed     Abstract available


    December 2018
  199. KAMATH GR, Tremblay D, Coltoff A, Caro J, et al
    Differences in the clinical and genetic profile of Hispanic and non-Hispanic acute myeloid leukemia patients.
    Leuk Res. 2018;77:1-4.
    PubMed    


  200. KIM HS, Han E, Jang W, Kim M, et al
    Germline CEBPA mutations in Korean patients with acute myeloid leukemia.
    Leuk Res. 2018 Dec 11. pii: S0145-2126(18)30490.
    PubMed    


  201. LETENDRE P, Doll D
    Novel therapeutics in the treatment of hairy cell leukemia variant.
    Leuk Res. 2018;75:58-60.
    PubMed    


    November 2018
  202. DE QUEIROZ MENDONCA C, Freire MV, Viana SS, Silva Tavares MKG, et al
    Ocular manifestations in acute lymphoblastic leukemia: A five-year cohort study of pediatric patients.
    Leuk Res. 2018;76:24-28.
    PubMed     Abstract available


  203. FILI C, Candoni A, Zannier ME, Olivieri J, et al
    Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Leuk Res. 2018;76:33-38.
    PubMed     Abstract available


  204. KANG KH, Kim SH, Choi SY, Yoo HL, et al
    Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia.
    Leuk Res. 2018 Nov 27. pii: S0145-2126(18)30444.
    PubMed     Abstract available


  205. BROOIMANS RA, van der Velden VHJ, Boeckx N, Slomp J, et al
    Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: Is multicentric MRD assessment feasible?
    Leuk Res. 2018;76:39-47.
    PubMed     Abstract available


  206. NAARMANN-DE VRIES IS, Sackmann Y, Klein F, Ostareck-Lederer A, et al
    Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region.
    Leuk Res. 2018;76:15-23.
    PubMed     Abstract available


  207. DA ROSA FC, Buque Pardinho R, Schultz Moreira ME, de Souza LGT, et al
    In vitro stability of arsenic trioxide-liposome encapsulates for acute promyelocytic leukemia treatment.
    Leuk Res. 2018;76:11-14.
    PubMed     Abstract available


  208. ITONAGA H, Ota S, Ikeda T, Taji H, et al
    Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan.
    Leuk Res. 2018;75:50-57.
    PubMed     Abstract available


  209. ANDO N, Furuichi Y, Kasai S, Tamai M, et al
    Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Leuk Res. 2018;75:36-44.
    PubMed     Abstract available


  210. FRIES C, Burack WR
    A clinical perspective on immunoglobulin heavy chain clonal heterogeneity in B cell acute lymphoblastic leukemia.
    Leuk Res. 2018;75:15-22.
    PubMed     Abstract available


  211. JAKOVIC L, Bogdanovic A, Djordjevic V, Dencic-Fekete M, et al
    The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities.
    Leuk Res. 2018;75:23-28.
    PubMed     Abstract available


  212. RAJ RV, Abedin SM, Atallah E
    Incorporating newer agents in the treatment of acute myeloid leukemia.
    Leuk Res. 2018;74:113-120.
    PubMed     Abstract available


    October 2018
  213. HUAN C, Jin L, Heng W, Na A, et al
    MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
    Leuk Res. 2018;75:1-6.
    PubMed     Abstract available


  214. VACHHANI P, Al Yacoub R, Miller A, Zhang F, et al
    Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
    Leuk Res. 2018;75:29-35.
    PubMed     Abstract available


  215. THEUNISSEN PMJ, de Bie M, van Zessen D, de Haas V, et al
    Next-generation antigen receptor sequencing of paired diagnosis and relapse samples of B-cell acute lymphoblastic leukemia: Clonal evolution and implications for minimal residual disease target selection.
    Leuk Res. 2018 Oct 22. pii: S0145-2126(18)30443.
    PubMed     Abstract available


  216. ARABANIAN LS, Johansson P, Staffas A, Nilsson T, et al
    The endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in acute myeloid leukemia.
    Leuk Res. 2018 Oct 13. pii: S0145-2126(18)30430.
    PubMed     Abstract available


  217. SWEET K, Hazlehurst L, Sahakian E, Powers J, et al
    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
    Leuk Res. 2018;74:89-96.
    PubMed     Abstract available


  218. BONIFACIO M, Scaffidi L, Binotto G, Miggiano MC, et al
    Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
    Leuk Res. 2018;74:75-79.
    PubMed     Abstract available


  219. MEDEIROS BC
    Chemotherapy based combinations in AML: Time to take a step back?
    Leuk Res. 2018;73:39-40.
    PubMed    


    September 2018
  220. ESKAZAN AE, Tiribelli M
    Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
    Leuk Res. 2018;74:55-56.
    PubMed    


  221. CHONG ML, Cheng H, Xu P, You H, et al
    TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid.
    Leuk Res. 2018;74:51-54.
    PubMed    


  222. JAMY O, Bae S, Costa LJ, Erba HP, et al
    Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrow.
    Leuk Res. 2018;74:64-67.
    PubMed     Abstract available


  223. NAKAMURA Y, Ichikawa M, Oda H, Yamazaki I, et al
    RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice.
    Leuk Res. 2018;74:14-20.
    PubMed     Abstract available


  224. BRASSESCO MS, Pezuk JA, Cortez MA, Bezerra Salomao K, et al
    TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;74:42-46.
    PubMed     Abstract available


  225. PODSHIVALOVA K, Wang EA, Hart T, Salomon DR, et al
    Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line.
    Leuk Res. 2018;74:1-9.
    PubMed     Abstract available


  226. BRUNNER AM, Kim PG, Sadrzadeh H, Drapkin BJ, et al
    Clustered incidence of adult acute promyelocytic leukemia.
    Leuk Res. 2018;74:47-50.
    PubMed    


  227. TODOERTI K, Calice G, Trino S, Simeon V, et al
    Global methylation patterns in primary plasma cell leukemia.
    Leuk Res. 2018;73:95-102.
    PubMed     Abstract available


  228. DE CARVALHO DC, Wanderley AV, Dos Santos AMR, Fernandes MR, et al
    Pharmacogenomics and variations in the risk of toxicity during the consolidation/maintenance phases of the treatment of pediatric B-cell leukemia patients from an admixed population in the Brazilian Amazon.
    Leuk Res. 2018;74:10-13.
    PubMed     Abstract available


  229. BLOCH J, Spertini O, Stucki A, Solly F, et al
    Over 20 years of treatment-free remission after interferon-alpha monotherapy for chronic myeloid leukemia.
    Leuk Res. 2018;73:103-104.
    PubMed    


  230. TALATI C, Sweet K
    Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Leuk Res. 2018;73:58-66.
    PubMed     Abstract available


  231. SAVOIE ML, Bence-Bruckler I, Huebsch LB, Lalancette M, et al
    Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
    Leuk Res. 2018;73:67-75.
    PubMed     Abstract available


  232. WU H, Liu B, Li B, Wang Y, et al
    Granular B-acute lymphoblastic leukemia: Ultrastructural characterization of cytoplasmic granules.
    Leuk Res. 2018;73:105-107.
    PubMed    


  233. SOMMER S, Cruijsen M, Claus R, Bertz H, et al
    Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Leuk Res. 2018;72:20-26.
    PubMed     Abstract available


    August 2018
  234. FERREYRO BL, Munshi L, Detsky ME, Minden MD, et al
    Acute promyelocytic leukemia in the intensive care unit: A retrospective analysis.
    Leuk Res. 2018;73:41-43.
    PubMed    


  235. HUDSON CA, Burack WR, Bennett JM
    Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia.
    Leuk Res. 2018;73:12-15.
    PubMed     Abstract available


  236. LI D, Lin TL, Lipe B, Hopkins RA, et al
    A novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristics.
    Leuk Res. 2018;72:105-112.
    PubMed     Abstract available


  237. CHEN X, Wang F, Zhang Y, Wang M, et al
    Retrospective analysis of 36 fusion genes in 2479 Chinese patients of de novo acute lymphoblastic leukemia.
    Leuk Res. 2018;72:99-104.
    PubMed     Abstract available


  238. DHANGAR S, C SK, S C, Vundinti BR, et al
    Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C-->A) of Bcr/Abl gene in a chronic myeloid leukemia patient.
    Leuk Res. 2018;72:96-98.
    PubMed    


  239. ZEIDNER JF, Foster MC, Blackford AL, Litzow MR, et al
    Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
    Leuk Res. 2018;72:92-95.
    PubMed    


  240. MANUKYAN G, Turcsanyi P, Mikulkova Z, Gabcova G, et al
    Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;72:113-119.
    PubMed     Abstract available


  241. LEI H, Yang L, Zhou L, Tong Y, et al
    Targeting acute myeloid leukemia CD34(+) stem/progenitor cells with small molecule inhibitor MK-8776.
    Leuk Res. 2018;72:71-73.
    PubMed    


  242. NAIR RR, Piktel D, Geldenhuys WJ, Gibson LF, et al
    Combination of cabazitaxel and plicamycin induces cell death in drug resistant B-cell acute lymphoblastic leukemia.
    Leuk Res. 2018;72:59-66.
    PubMed     Abstract available


    July 2018
  243. FERRARO F, Gao F, Stockerl-Goldstein K, Westervelt P, et al
    Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.
    Leuk Res. 2018;72:86-91.
    PubMed     Abstract available


  244. DARVISHI M, Mashati P, Khosravi A
    The clinical significance of CDX2 in leukemia: A new perspective for leukemia research.
    Leuk Res. 2018;72:45-51.
    PubMed     Abstract available


  245. WANG YZ, Hao L, Chang Y, Jiang Q, et al
    A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype.
    Leuk Res. 2018;72:12-19.
    PubMed     Abstract available


  246. ROUSSELOT P, Renard P, de Buyer A, Finet A, et al
    Nivolumab to control molecular response in chronic myeloid leukemia.
    Leuk Res. 2018;72:5-6.
    PubMed    


  247. HEIBLIG M, Elhamri M, Thomas X, Plesa A, et al
    A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemia.
    Leuk Res. 2018;72:7-11.
    PubMed    


  248. RADIVOYEVITCH T, Dean RM, Shaw BE, Brazauskas R, et al
    Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
    Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160.
    PubMed     Abstract available


  249. GU Y, Han Q, McGrath M, Song C, et al
    Clinical significance of novel SH2B3 mutations in adult Chinese acute lymphoblastic leukemia patients.
    Leuk Res. 2018;72:67-70.
    PubMed    


  250. MARZ M, Meyer S, Erb U, Georgikou C, et al
    Pediatric acute lymphoblastic leukemia-Conquering the CNS across the choroid plexus.
    Leuk Res. 2018;71:47-54.
    PubMed     Abstract available


  251. ARCHIBALD WJ, Meacham PJ, Williams AM, Baran AM, et al
    Management of melanoma in patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;71:43-46.
    PubMed     Abstract available


    June 2018
  252. WARRICK K, Althouse SK, Rahrig A, Rupenthal J, et al
    Factors associated with a prolonged hospital stay during induction chemotherapy in newly diagnosed high risk pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;71:36-42.
    PubMed     Abstract available


  253. BELL JA, Galaznik A, Farrelly E, Blazer M, et al
    Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
    Leuk Res. 2018;71:27-33.
    PubMed     Abstract available


  254. ROSSI JG, Rubio P, Alonso CN, Bernasconi AR, et al
    Cytoplasmic CD3 expression in infant acute megakaryoblastic leukemia: A new ambiguous lineage subtype?
    Leuk Res. 2018;71:6-12.
    PubMed     Abstract available


  255. PAN T, Qi J, You T, Yang L, et al
    Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort st
    Leuk Res. 2018;71:13-24.
    PubMed     Abstract available


  256. GAVILLET M, Spertini O, Blum S
    Pseudo Chediak-Higashi anomaly in blasts from acute lymphoblastic leukemia.
    Leuk Res. 2018;70:87-90.
    PubMed    


  257. DAS S, Dielschneider R, Chanas-LaRue A, Johnston JB, et al
    Antimalarial drugs trigger lysosome-mediated cell death in chronic lymphocytic leukemia (CLL) cells.
    Leuk Res. 2018;70:79-86.
    PubMed     Abstract available


  258. BRYANT AL, Drier SW, Lee S, Bennett AV, et al
    A systematic review of patient reported outcomes in phase II or III clinical trials of myelodysplastic syndromes and acute myeloid leukemia.
    Leuk Res. 2018;70:106-116.
    PubMed     Abstract available


  259. LEE SE, Choi SY, Kim SH, Jootar S, et al
    Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib.
    Leuk Res. 2018;70:100-105.
    PubMed     Abstract available


  260. LIU C, Wei H, Yao X, Liu B, et al
    Retraction notice to "Arsenic Trioxide Inhibits Proliferation and Induced apoptosis of Leukemia Stem Cells with Drug Resistance " [LR 69 (2018) 66-71].
    Leuk Res. 2018;69:103.
    PubMed    


  261. VULAJ V, Perissinotti AJ, Uebel JR, Nachar VR, et al
    The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia.
    Leuk Res. 2018;70:91-96.
    PubMed     Abstract available


  262. WANG ES, O'Dwyer K
    High dose daunorubicin: New standard of care for FLT3 ITD mutant AML.
    Leuk Res. 2018;69:87-88.
    PubMed    


  263. CHEN Z, Kapus A, Khatri I, Kos O, et al
    Cell membrane-bound CD200 signals both via an extracellular domain and following nuclear translocation of a cytoplasmic fragment.
    Leuk Res. 2018;69:72-80.
    PubMed     Abstract available


    May 2018
  264. WANG W, Routbort MJ, Loghavi S, Tang Z, et al
    Characterization of chronic myelomonocytic leukemia with TP53 mutations.
    Leuk Res. 2018;70:97-99.
    PubMed    


  265. XICOY B, Triguero A, Such E, Garcia O, et al
    The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
    Leuk Res. 2018;70:34-36.
    PubMed    


  266. MADAROVA M, Mucha R, Hresko S, Makarova Z, et al
    Identification of new phosphorylation sites of CD23 in B-cells of patients with chronic lymphocytic leukemia.
    Leuk Res. 2018;70:25-33.
    PubMed     Abstract available


  267. SMITH MR, Weiss RF
    Optimal use of novel agents in chronic lymphocytic leukemia.
    Leuk Res. 2018;70:37-40.
    PubMed     Abstract available


  268. HUANG J, Wang Z, Huang L, Zheng M, et al
    Corrigendum to 'CD41 immune staining of micromegakaryocytes improves the diagnosis of myelodysplastic syndrome and differentiation from pancytopenia' [leukemia research. 2018; 66: 15-19].
    Leuk Res. 2018;68:120.
    PubMed    


  269. SHOKRI G, Doudi S, Fathi-Roudsari M, Kouhkan F, et al
    Targeting histone demethylases KDM5A and KDM5B in AML cancer cells: A comparative view.
    Leuk Res. 2018;68:105-111.
    PubMed     Abstract available


  270. ZHU F, Khatri I, Spaner D, Gorczynski RM, et al
    An autologous tumor vaccine for CLL.
    Leuk Res. 2018;68:40-47.
    PubMed     Abstract available


  271. KAVANAGH S, Heath E, Hurren R, Gronda M, et al
    AML refractory to primary induction with Ida-FLAG has a poor clinical outcome.
    Leuk Res. 2018;68:22-28.
    PubMed     Abstract available


  272. LIU J, Lu W, Liu S, Wang Y, et al
    ZFP36L2, a novel AML1 target gene, induces AML cells apoptosis and inhibits cell proliferation.
    Leuk Res. 2018;68:15-21.
    PubMed     Abstract available


  273. IRIYAMA N, Takahashi H, Miura K, Uchino Y, et al
    Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
    Leuk Res. 2018;68:1-8.
    PubMed     Abstract available


    April 2018
  274. PAPAGEORGIOU SG, Kontos CK, Tsiakanikas P, Stavroulaki G, et al
    Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
    Leuk Res. 2018;70:1-7.
    PubMed     Abstract available


  275. TAN Y, Liu Z, Wang W, Zhu G, et al
    Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia.
    Leuk Res. 2018;69:89-93.
    PubMed     Abstract available


  276. ZHANG M, Yin J, He Q, Zhang F, et al
    Chinese and Europeans with acute myeloid leukemia have discordant mutation topographies.
    Leuk Res. 2018;70:8-12.
    PubMed     Abstract available


  277. DELORD M, Foulon S, Cayuela JM, Rousselot P, et al
    The rising prevalence of chronic myeloid leukemia in France.
    Leuk Res. 2018;69:94-99.
    PubMed     Abstract available


  278. TANG L, Wang N, Xing C, Zhuang Q, et al
    Effect of absolute monocyte count post-transplant on the outcome of patients with acute myeloid leukemia undergoing myeloablative allogeneic hematopoietic stem cell transplant with busulfan and cyclophosphamide conditioning.
    Leuk Res. 2018;69:60-65.
    PubMed     Abstract available


  279. GROHMANN T, Penke M, Petzold-Quinque S, Schuster S, et al
    Inhibition of NAMPT sensitizes MOLT4 leukemia cells for etoposide treatment through the SIRT2-p53 pathway.
    Leuk Res. 2018;69:39-46.
    PubMed     Abstract available


  280. GHAVAMZADEH A, Jalili M, Rostami S, Yaghmaie M, et al
    Corrigendum to: Comparison of Induction Therapy in Non-high Risk Acute Promyelocytic Leukemia with Arsenic Trioxide or in Combination with ATRA Leukemia Research 66 (2018) 85-88.
    Leuk Res. 2018;67:116.
    PubMed    


  281. WANG YH, Imai Y, Shiseki M, Tanaka J, et al
    Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1/P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation.
    Leuk Res. 2018;67:99-108.
    PubMed     Abstract available


  282. ANNIBALI O, Crescenzi A, Tomarchio V, Pagano A, et al
    PD-1 /PD-L1 checkpoint in hematological malignancies.
    Leuk Res. 2018;67:45-55.
    PubMed     Abstract available


    March 2018
  283. PEHLIVAN M, Caliskan C, Yuce Z, Sercan HO, et al
    Secreted Wnt antagonists in leukemia: A road yet to be paved.
    Leuk Res. 2018;69:24-30.
    PubMed     Abstract available


  284. LAM CF, Yeung HT, Lam YM, Ng RK, et al
    Reactive oxygen species activate differentiation gene transcription of acute myeloid leukemia cells via the JNK/c-JUN signaling pathway.
    Leuk Res. 2018;68:112-119.
    PubMed     Abstract available


  285. SAROVA I, Brezinova J, Zemanova Z, Ransdorfova S, et al
    High frequency of dicentric chromosomes detected by multi-centromeric FISH in patients with acute myeloid leukemia and complex karyotype.
    Leuk Res. 2018;68:85-89.
    PubMed     Abstract available


  286. RIBERA JM, Garcia O, Gil C, Mercadal S, et al
    Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55-65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Res. 2018;68:79-84.
    PubMed     Abstract available


  287. CHOI EJ, Lee JH, Lee JH, Park HS, et al
    Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.
    Leuk Res. 2018;68:51-56.
    PubMed     Abstract available


  288. SEDDON AN, Chaim J, Akin O, Drill E, et al
    Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Leuk Res. 2018;68:48-50.
    PubMed     Abstract available


  289. SCHOEN MW, Woelich SK, Braun JT, Reddy DV, et al
    Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Leuk Res. 2018;68:72-78.
    PubMed     Abstract available


  290. DAI Q, Liu X, Yang H, Guo S, et al
    No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
    Leuk Res. 2018;68:57-61.
    PubMed     Abstract available


  291. LIU C, Wei H, Yao X, Liu B, et al
    Arsenic trioxide inhibits proliferation and induced apoptosis of leukemia stem cells with drug resistance.
    Leuk Res. 2018;69:66-71.
    PubMed     Abstract available


  292. GANZEL C, Rouvio O, Avivi I, Magen H, et al
    Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
    Leuk Res. 2018;68:9-14.
    PubMed     Abstract available


  293. SINGH M, Bhatia P, Trehan A, Varma N, et al
    High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction.
    Leuk Res. 2018;66:79-84.
    PubMed     Abstract available


  294. NAJIMA Y, Yoshida C, Iriyama N, Fujisawa S, et al
    Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
    Leuk Res. 2018;66:66-72.
    PubMed     Abstract available


    February 2018
  295. SAILLARD C, Elkaim E, Rey J, d'Incan E, et al
    Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients.
    Leuk Res. 2018;68:29-31.
    PubMed    


  296. HIWASE D, Tan P, D'Rozario J, Taper J, et al
    Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Leuk Res. 2018;67:109-115.
    PubMed     Abstract available


  297. DECKERT AL, Gheihman G, Nissim R, Chung C, et al
    The importance of meaningful activity in people living with acute myeloid leukemia.
    Leuk Res. 2018;67:86-91.
    PubMed     Abstract available


  298. LI X, Li D, Huang X, Zhou P, et al
    Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia.
    Leuk Res. 2018;67:60-66.
    PubMed     Abstract available


  299. EPSTEIN-PETERSON ZD, Devlin SM, Stein EM, Estey E, et al
    Widespread use of measurable residual disease in acute myeloid leukemia practice.
    Leuk Res. 2018;67:92-98.
    PubMed     Abstract available


  300. MEDEIROS BC
    Interpretation of clinical endpoints in trials of acute myeloid leukemia.
    Leuk Res. 2018;68:32-39.
    PubMed     Abstract available


  301. TOSIC N, Petrovic I, Grujicic NK, Davidovic S, et al
    Prognostic significance of SOX2, SOX3, SOX11, SOX14 and SOX18 gene expression in adult de novo acute myeloid leukemia.
    Leuk Res. 2018;67:32-38.
    PubMed     Abstract available


  302. BLAKLEY MP, Dutcher JP, Wiernik PH
    Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature.
    Leuk Res. 2018;67:39-44.
    PubMed     Abstract available


  303. HEINRICHS A, Dessars B, El Housni H, Pluymers W, et al
    Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
    Leuk Res. 2018;67:27-31.
    PubMed     Abstract available


  304. HU Z, Hu S, Ji C, Tang Z, et al
    3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
    Leuk Res. 2018;65:25-28.
    PubMed     Abstract available


  305. SCHULER E, Frank F, Hildebrandt B, Betz B, et al
    Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Leuk Res. 2018;65:1-4.
    PubMed     Abstract available


    January 2018
  306. ADVANI AS, Li H, Michaelis LC, Medeiros BC, et al
    Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).
    Leuk Res. 2018;67:17-20.
    PubMed     Abstract available


  307. GHAVAMZADEH A, Jalili M, Rostami S, Yaghmaie M, et al
    Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
    Leuk Res. 2018;66:85-88.
    PubMed     Abstract available


  308. PETITI J, Rosso V, Lo Iacono M, Calabrese C, et al
    Prognostic significance of The Wilms' Tumor-1 (WT1) rs16754 polymorphism in acute myeloid leukemia.
    Leuk Res. 2018;67:6-11.
    PubMed     Abstract available


  309. DHOLARIA BR, Ayala E, Sokol L, Nishihori T, et al
    Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Leuk Res. 2018;67:1-5.
    PubMed     Abstract available


  310. HARADA Y, Nagata Y, Kihara R, Ishikawa Y, et al
    Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.
    Leuk Res. 2018;66:20-27.
    PubMed     Abstract available


  311. ZHU F, McCaw L, Spaner DE, Gorczynski RM, et al
    Targeting the IL-17/IL-6 axis can alter growth of Chronic Lymphocytic Leukemia in vivo/in vitro.
    Leuk Res. 2018;66:28-38.
    PubMed     Abstract available


  312. AMANZADEH A, Molla-Kazemiha V, Samani S, Habibi-Anbouhi M, et al
    New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells.
    Leuk Res. 2018;68:98-104.
    PubMed     Abstract available


  313. GETTA BM, Devlin S, Park JH, Tallman MS, et al
    Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia.
    Leuk Res. 2018;65:80-85.
    PubMed     Abstract available


  314. INOKUCHI K, Nakayama K, Tauchi T, Takaku T, et al
    Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
    Leuk Res. 2018;65:74-79.
    PubMed     Abstract available


  315. KONG YL, Huang Y, Wu JZ, Cao X, et al
    Expression of autophagy related genes in chronic lymphocytic leukemia is associated with disease course.
    Leuk Res. 2018;66:8-14.
    PubMed     Abstract available


  316. BURKE PW, Aldoss I, Lunning MA, Devlin SM, et al
    Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
    Leuk Res. 2018;66:49-56.
    PubMed     Abstract available


  317. OKABE-KADO J, Hagiwara-Watanabe Y, Niitsu N, Kasukabe T, et al
    NM23 downregulation and lysophosphatidic acid receptor EDG2/lpa1 upregulation during myeloid differentiation of human leukemia cells.
    Leuk Res. 2018;66:39-48.
    PubMed     Abstract available


  318. CUI P, Zhang Y, Cui M, Li Z, et al
    Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation.
    Leuk Res. 2018;65:49-54.
    PubMed     Abstract available


  319. KAMIJO R, Itonaga H, Kihara R, Nagata Y, et al
    Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.
    Leuk Res. 2018;65:34-41.
    PubMed     Abstract available


  320. JAWOROWSKA A, Pastorczak A, Trelinska J, Wypyszczak K, et al
    Perforin gene variation influences survival in childhood acute lymphoblastic leukemia.
    Leuk Res. 2018;65:29-33.
    PubMed     Abstract available


  321. STRICKLAND SA, Shaver AC, Byrne M, Daber RD, et al
    Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
    Leuk Res. 2018;65:67-73.
    PubMed     Abstract available


  322. WANG SM, Zeng WX, Wu WS, Sun LL, et al
    Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
    Leuk Res. 2018;65:61-66.
    PubMed     Abstract available


  323. ZHAO H, Zhu H, Huang J, Zhu Y, et al
    The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia.
    Leuk Res. 2018;66:1-7.
    PubMed     Abstract available


  324. MILLAN NC, Pastrana A, Guitter MR, Zubizarreta PA, et al
    Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia.
    Leuk Res. 2018;65:86-93.
    PubMed     Abstract available


  325. MIYATA S, Wang LY, Kitanaka S
    3EZ, 20Ac-ingenol induces cell-specific apoptosis in cyclin D1 over-expression through the activation of ATR and downregulation of p-Akt.
    Leuk Res. 2018;64:46-51.
    PubMed     Abstract available


  326. GARCIA TB, Fosmire SP, Porter CC
    Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Leuk Res. 2018;64:30-33.
    PubMed     Abstract available


    December 2017
  327. ZHAN D, Zhang Y, Xiao P, Zheng X, et al
    Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia.
    Leuk Res. 2017;65:20-24.
    PubMed     Abstract available


  328. CULL AH, Mahendru D, Snetsinger B, Good D, et al
    Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Leuk Res. 2017;65:5-13.
    PubMed     Abstract available


  329. SEBERT M, Komrokji RS, Sekeres MA, Prebet T, et al
    Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Leuk Res. 2017;63:72-77.
    PubMed     Abstract available


  330. KOJIMA S, Nishioka C, Chi S, Yokoyama A, et al
    In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome.
    Leuk Res. 2017;63:1-9.
    PubMed     Abstract available


    November 2017
  331. PANDO A, Reagan JL, Quesenberry P, Fast LD, et al
    Extracellular vesicles in leukemia.
    Leuk Res. 2017;64:52-60.
    PubMed     Abstract available


  332. ZHU HH, Guo ZP, Jia JS, Jiang Q, et al
    The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia.
    Leuk Res. 2017;65:14-19.
    PubMed     Abstract available


  333. LEI H, Jin J, Liu M, Li X, et al
    Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
    Leuk Res. 2017;64:17-23.
    PubMed     Abstract available


  334. NAVADA SC, Fruchtman SM, Odchimar-Reissig R, Demakos EP, et al
    A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
    Leuk Res. 2017;64:10-16.
    PubMed     Abstract available


  335. SWORDS RT, Azzam D, Al-Ali H, Lohse I, et al
    Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.
    Leuk Res. 2017;64:34-41.
    PubMed     Abstract available


  336. SAJWANI FH, Collin P, Adrian TE
    Frondoside A potentiates the effects of conventional therapeutic agents in acute leukemia.
    Leuk Res. 2017;63:98-108.
    PubMed     Abstract available


  337. NACHAR VR, Perissinotti AJ, Scappaticci GB, Bixby DL, et al
    Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment.
    Leuk Res. 2017;63:56-61.
    PubMed     Abstract available


  338. TAN M, Rong Y, Su Q, Chen Y, et al
    Artesunate induces apoptosis via inhibition of STAT3 in THP-1 cells.
    Leuk Res. 2017;62:98-103.
    PubMed     Abstract available


  339. SINGH M, Bhatia P, Khera S, Trehan A, et al
    Emerging role of NUDT15 polymorphisms in 6-mercaptopurine metabolism and dose related toxicity in acute lymphoblastic leukaemia.
    Leuk Res. 2017;62:17-22.
    PubMed     Abstract available


    October 2017
  340. OZDOGAN H, Gur Dedeoglu B, Oztemur Islakoglu Y, Aydos A, et al
    DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Leuk Res. 2017;63:62-71.
    PubMed     Abstract available


  341. ERIKSSON A, Chantzi E, Fryknas M, Gullbo J, et al
    Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects.
    Leuk Res. 2017;63:41-46.
    PubMed     Abstract available


  342. NOMDEDEU M, Pereira A, Calvo X, Colomer J, et al
    Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group.
    Leuk Res. 2017;63:85-89.
    PubMed     Abstract available


  343. ZHAO WH, Huang BT, Zhang JY, Zeng QC, et al
    Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
    Leuk Res. 2017;63:28-33.
    PubMed     Abstract available


  344. CANDONI A, De Marchi F, Zannier ME, Lazzarotto D, et al
    High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Leuk Res. 2017;63:22-27.
    PubMed     Abstract available


  345. FAKHIMAHMADI A, Nazmi F, Rahmati M, Bonab NM, et al
    Nucleostemin silencing induces differentiation and potentiates all-trans-retinoic acid effects in human acute promyelocytic leukemia NB4 cells via autophagy.
    Leuk Res. 2017;63:15-21.
    PubMed     Abstract available


  346. MOHAMMADI SM, Mohammadnejad D, Hosseinpour Feizi AA, Movassaghpour AA, et al
    Inhibition of c-REL using siRNA increased apoptosis and decreased proliferation in pre-B ALL blasts: Therapeutic implications.
    Leuk Res. 2017;61:53-61.
    PubMed     Abstract available


  347. AIRIAU K, Turcq B, Mahon FX, Belloc F, et al
    A new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line.
    Leuk Res. 2017;61:44-52.
    PubMed     Abstract available


    September 2017
  348. HENKENIUS K, Greene BH, Barckhausen C, Hartmann R, et al
    Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia.
    Leuk Res. 2017;62:56-63.
    PubMed     Abstract available


  349. AHMED T, Koch AL, Isom S, Klepin HD, et al
    Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit.
    Leuk Res. 2017;62:51-55.
    PubMed     Abstract available


  350. HUANG Y, Zou Y, Lin L, Ma X, et al
    Effect of BIX-01294 on proliferation, apoptosis and histone methylation of acute T lymphoblastic leukemia cells.
    Leuk Res. 2017;62:34-39.
    PubMed     Abstract available


  351. ZHOU K, Song Y, Zhang Y, Wei X, et al
    Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
    Leuk Res. 2017;62:29-33.
    PubMed     Abstract available


  352. VISANI G, Ferrara F, Di Raimondo F, Loscocco F, et al
    Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.
    Leuk Res. 2017;62:77-83.
    PubMed     Abstract available


  353. BOUVY C, Wannez A, Laloy J, Chatelain C, et al
    Transfer of multidrug resistance among acute myeloid leukemia cells via extracellular vesicles and their microRNA cargo.
    Leuk Res. 2017;62:70-76.
    PubMed     Abstract available


  354. SAHAI T, Henrichs K, Refaai M, Heal JM, et al
    ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
    Leuk Res. 2017;62:1-3.
    PubMed     Abstract available


  355. AZUMA K, Umezu T, Imanishi S, Asano M, et al
    Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing.
    Leuk Res. 2017;62:23-28.
    PubMed     Abstract available


  356. WEBSTER JA, Tibes R, Morris L, Blackford AL, et al
    Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
    Leuk Res. 2017;61:108-116.
    PubMed     Abstract available


  357. HORSTER L, Schlenk RF, Stadler M, Gabriel M, et al
    Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype.
    Leuk Res. 2017;62:84-90.
    PubMed     Abstract available


  358. WANG F, Jia JS, Wang J, Zhao T, et al
    The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Leuk Res. 2017;61:84-88.
    PubMed     Abstract available


  359. DARJI A, Desai N, Modi R, Khamar B, et al
    Establishment of cell line with NK/NKT phenotype from myeloid NK cell acute leukemia.
    Leuk Res. 2017;61:77-83.
    PubMed     Abstract available


  360. TAMAI M, Furuichi Y, Kasai S, Ando N, et al
    TGFbeta1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Leuk Res. 2017;61:68-76.
    PubMed     Abstract available


  361. CHEN CY, Chang PC, Wang TH, Wang TV, et al
    The in vivo anti-leukemia activity of N-(1-Pyrenlyl) maleimide in a bioluminescent mouse model.
    Leuk Res. 2017;62:64-69.
    PubMed     Abstract available


  362. KRUG U, Gale RP, Berdel WE, Muller-Tidow C, et al
    Therapy of older persons with acute myeloid leukaemia.
    Leuk Res. 2017;60:1-10.
    PubMed     Abstract available


    August 2017
  363. YOUNESIAN S, Shahkarami S, Ghaffari P, Alizadeh S, et al
    DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
    Leuk Res. 2017;61:33-38.
    PubMed     Abstract available


  364. NORSWORTHY KJ, DeZern AE, Tsai HL, Hand WA, et al
    Timed sequential therapy for acute myelogenous leukemia: Results of a retrospective study of 301 patients and review of the literature.
    Leuk Res. 2017;61:25-32.
    PubMed     Abstract available


  365. COMONT T, Tavitian S, Bardiaux L, Fort M, et al
    Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.
    Leuk Res. 2017;61:62-67.
    PubMed     Abstract available


  366. FRAIRIA C, Aydin S, Audisio E, Riera L, et al
    Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study.
    Leuk Res. 2017;61:10-17.
    PubMed     Abstract available


  367. CHEN Y, Pourabdollah M, Atenafu EG, Tierens A, et al
    Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
    Leuk Res. 2017;61:39-43.
    PubMed     Abstract available


  368. CAOCCI G, Greco M, Arras M, Cusano R, et al
    HLA-G molecules and clinical outcome in Chronic Myeloid Leukemia.
    Leuk Res. 2017;61:1-5.
    PubMed     Abstract available


  369. SAKIHAMA S, Saito M, Kuba-Miyara M, Tomoyose T, et al
    Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lym
    Leuk Res. 2017;61:18-24.
    PubMed     Abstract available


  370. YAO C, Zhang G, Walker A, Zhao KY, et al
    Potent induction of apoptosis by givinostat in BCR-ABL1-positive and BCR-ABL1-negative precursor B-cell acute lymphoblastic leukemia cell lines.
    Leuk Res. 2017;60:129-134.
    PubMed     Abstract available


  371. VAVROVA E, Kantorova B, Vonkova B, Kabathova J, et al
    Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia.
    Leuk Res. 2017;60:145-150.
    PubMed     Abstract available


  372. MASAROVA L, Bose P, Daver N, Pemmaraju N, et al
    Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Leuk Res. 2017;59:110-116.
    PubMed     Abstract available


  373. HERSHENFELD SA, Maki K, Rothfels L, Murray CS, et al
    Sharing post-AML consolidation supportive therapy with local centers reduces patient travel burden without compromising outcomes.
    Leuk Res. 2017;59:93-96.
    PubMed     Abstract available


  374. VALENT P, Hadzijusufovic E, Hoermann G, Fureder W, et al
    Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.
    Leuk Res. 2017;59:47-54.
    PubMed     Abstract available


  375. LEISCH M, Weiss L, Lindlbauer N, Jungbauer C, et al
    Red blood cell alloimmunization in 184 patients with myeloid neoplasms treated with azacitidine - A retrospective single center experience.
    Leuk Res. 2017;59:12-19.
    PubMed     Abstract available


    July 2017
  376. AGGOUNE D, Sorel N, Bonnet ML, Goujon JM, et al
    Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs).
    Leuk Res. 2017;60:94-102.
    PubMed     Abstract available


  377. MPAKOU VE, Ioannidou HD, Konsta E, Vikentiou M, et al
    Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia.
    Leuk Res. 2017;60:74-81.
    PubMed     Abstract available


  378. BENICIO MTL, Ribeiro AFT, Americo AD, Furtado FM, et al
    Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.
    Leuk Res. 2017;60:109-114.
    PubMed     Abstract available


  379. SUKEGAWA M, Wang X, Nishioka C, Pan B, et al
    The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1beta in vascular endothelium in association with downregulation of miR-3p.
    Leuk Res. 2017;58:83-90.
    PubMed     Abstract available


  380. SZURIAN K, Csala I, Piurko V, Deak L, et al
    Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression.
    Leuk Res. 2017;58:39-42.
    PubMed     Abstract available


  381. LI D, Gale RP, Liu Y, Lei B, et al
    5'-Triphosphate siRNA targeting MDR1 reverses multi-drug resistance and activates RIG-I-induced immune-stimulatory and apoptotic effects against human myeloid leukaemia cells.
    Leuk Res. 2017;58:23-30.
    PubMed     Abstract available


    June 2017
  382. BLUM S, Martins F, Lubbert M
    Immunotherapy in adult acute leukemia.
    Leuk Res. 2017;60:63-73.
    PubMed     Abstract available


  383. ALABDULWAHAB AS, Elsayed HG, Sherisher MA, Zeeneldin A, et al
    The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Leuk Res. 2017;60:58-62.
    PubMed     Abstract available


  384. KIM T, Tyndel MS, Zhang Z, Ahn J, et al
    Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.
    Leuk Res. 2017;59:142-148.
    PubMed     Abstract available


  385. CHEN L, Guo P, Zhang Y, Li X, et al
    Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
    Leuk Res. 2017;60:44-52.
    PubMed     Abstract available


  386. HUANG M, Miyake K, Kagami K, Abe M, et al
    Lack of association between deletion polymorphism of BIM gene and in vitro drug sensitivity in B-cell precursor acute lymphoblastic leukemia.
    Leuk Res. 2017;60:24-30.
    PubMed     Abstract available


  387. JAIN P, Wang S, Patel KP, Sarwari N, et al
    Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.
    Leuk Res. 2017;59:105-109.
    PubMed     Abstract available


  388. VAZQUEZ-REYES A, Bobadilla-Morales L, Barba-Barba C, Macias-Salcedo G, et al
    Aneuploidy identification in pre-B acute lymphoblastic leukemia patients at diagnosis by Multiplex Ligation-dependent Probe Amplification (MLPA).
    Leuk Res. 2017;59:117-123.
    PubMed     Abstract available


  389. CHEN H, Liu KY, Xu LP, Chen YH, et al
    Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era.
    Leuk Res. 2017;59:136-141.
    PubMed     Abstract available


  390. POPP HD, Naumann N, Brendel S, Henzler T, et al
    Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
    Leuk Res. 2017;57:112-118.
    PubMed     Abstract available


  391. STRUPP C, Nachtkamp K, Hildebrandt B, Giagounidis A, et al
    New proposals of the WHO working group (2016) for the diagnosis of myelodysplastic syndromes (MDS): Characteristics of refined MDS types.
    Leuk Res. 2017;57:78-84.
    PubMed     Abstract available


  392. SADRAS T, Kok CH, Perugini M, Ramshaw HS, et al
    miR-155 as a potential target of IL-3 signaling in primary AML cells.
    Leuk Res. 2017;57:57-59.
    PubMed     Abstract available


  393. HILAL T, Slone S, Peterson S, Bodine C, et al
    Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy.
    Leuk Res. 2017;57:37-44.
    PubMed     Abstract available


    May 2017
  394. ISHDORJ G, Kost SEF, Beiggi S, Zang Y, et al
    A novel spliced variant of the TIN2 shelterin is present in chronic lymphocytic leukemia.
    Leuk Res. 2017;59:66-74.
    PubMed     Abstract available


  395. YANG H, Fang Z, Wei Y, Bohannan ZS, et al
    Preclinical activity of FF-10501-01, a novel inosine-5'-monophosphate dehydrogenase inhibitor, in acute myeloid leukemia.
    Leuk Res. 2017;59:85-92.
    PubMed     Abstract available


  396. YAP E, Norziha ZA, Simbun A, Tumian NR, et al
    MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
    Leuk Res. 2017;59:32-40.
    PubMed     Abstract available


  397. GU B, Wu X, Chen G, Ma X, et al
    Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Res. 2017;59:41-46.
    PubMed     Abstract available


  398. DUAN MH, Li H, Cai H
    A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Leuk Res. 2017;59:8-11.
    PubMed     Abstract available


  399. TAN J, Wang Y, Yu SJ, Ma YY, et al
    Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.
    Leuk Res. 2017;59:1-7.
    PubMed     Abstract available


  400. STRICKLAND SA, Sun Z, Ketterling RP, Cherry AM, et al
    Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.
    Leuk Res. 2017;59:55-64.
    PubMed     Abstract available


  401. KUMAR B, Kalvala A, Chu S, Rosen S, et al
    Antileukemic activity and cellular effects of the antimalarial agent artesunate in acute myeloid leukemia.
    Leuk Res. 2017;59:124-135.
    PubMed     Abstract available


  402. GOPALAKRISHNAPILLAI A, Kolb EA, McCahan SM, Barwe SP, et al
    Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Leuk Res. 2017;58:91-97.
    PubMed     Abstract available


  403. LYONS RM, Marek BJ, Paley C, Esposito J, et al
    Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.
    Leuk Res. 2017;56:88-95.
    PubMed     Abstract available


  404. PATEL S, Mason CC, Glenn MJ, Paxton CN, et al
    Genomic analysis of adult B-ALL identifies potential markers of shorter survival.
    Leuk Res. 2017;56:44-51.
    PubMed     Abstract available


    April 2017
  405. MEDINGER M, Zeiter D, Heim D, Halter J, et al
    Hypothyroidism following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.
    Leuk Res. 2017;58:43-47.
    PubMed     Abstract available


  406. JASTANIAH W, Alsultan A, Al Daama S, Ballourah W, et al
    Treatment results in children with myeloid leukemia of Down syndrome in Saudi Arabia: A multicenter SAPHOS leukemia group study.
    Leuk Res. 2017;58:48-54.
    PubMed     Abstract available


  407. TIRIBELLI M, Raspadori D, Geromin A, Cavallin M, et al
    High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
    Leuk Res. 2017;58:31-38.
    PubMed     Abstract available


  408. YANG Y, Ding L, Guo ZK, Zheng XL, et al
    The epigenetically-regulated miR-34a targeting c-SRC suppresses RAF/MEK/ERK signaling pathway in K-562 cells.
    Leuk Res. 2017;55:91-96.
    PubMed     Abstract available


  409. PASIC I, Lipton JH
    Current approach to the treatment of chronic myeloid leukaemia.
    Leuk Res. 2017;55:65-78.
    PubMed     Abstract available


  410. ANNEREAU M, Willekens C, El Halabi L, Chahine C, et al
    Use of 5-azacitidine for therapy-related myeloid neoplasms in patients with concomitant active neoplastic disease.
    Leuk Res. 2017;55:58-64.
    PubMed     Abstract available


  411. CHIEN WW, Niogret C, Juge R, Lionnard L, et al
    Unexpected cross-reactivity of anti-cathepsin B antibodies leads to uncertainties regarding the mechanism of action of anti-CD20 monoclonal antibody GA101.
    Leuk Res. 2017;55:41-48.
    PubMed     Abstract available


  412. GUR HD, Wang SA, Tang Z, Hu S, et al
    Clinical significance of isolated del(7p) in myeloid neoplasms.
    Leuk Res. 2017;55:18-22.
    PubMed     Abstract available


    March 2017
  413. LI Y, Liu X, Guo X, Liu X, et al
    DNA methyltransferase 1 mediated aberrant methylation and silencing of SHP-1 gene in chronic myelogenous leukemia cells.
    Leuk Res. 2017;58:9-13.
    PubMed     Abstract available


  414. BILOUS N, Abramenko I, Saenko V, Chumak A, et al
    Clinical relevance of TP53 polymorphic genetic variations in chronic lymphocytic leukemia.
    Leuk Res. 2017;58:1-8.
    PubMed     Abstract available


  415. GARCIA C, Rosen A, Kimby E, Aguilar-Santelises M, et al
    Erratum to "Higher T-cell imbalance and growth factor receptor expression in B-cell chronic lymphocytic leukemia (B-CLL) as compared to monoclonal B-cell lymphocytosis of undetermined significance (B-MLUS)" [Leukemia Res. 13(1) (1989) 31-37].
    Leuk Res. 2017 Mar 14. pii: S0145-2126(17)30041.
    PubMed    


    February 2017
  416. GORDON MJ, Tardi P, Loriaux MM, Spurgeon SE, et al
    CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Leuk Res. 2017;53:39-49.
    PubMed     Abstract available


    December 2016
  417. LAZZAROTTO D, Candoni A, Fili C, Forghieri F, et al
    Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey.
    Leuk Res. 2016;53:74-81.
    PubMed     Abstract available


  418. HEINI AD, Berger MD, Seipel K, Taleghani BM, et al
    Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
    Leuk Res. 2016;53:28-34.
    PubMed     Abstract available


    May 2016
  419. MEDINGER M, Heim D, Gerull S, Halter J, et al
    Increase of endothelial progenitor cells in acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.
    Leuk Res. 2016;47:22-25.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: